Athira Pharma (NASDAQ:LONA) Stock Rating Upgraded by Mizuho

Athira Pharma (NASDAQ:LONA) was upgraded by stock analysts at Mizuho from a “neutral” rating to an “outperform” rating in a research note issued to investors on Thursday, Marketbeat.com reports. The firm currently has a $10.00 price objective on the stock. Mizuho’s price objective suggests a potential upside of 110.08% from the stock’s previous close.

LONA has been the subject of several other research reports. Weiss Ratings assumed coverage on Athira Pharma in a report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research report on Saturday, February 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Athira Pharma has an average rating of “Hold” and an average target price of $10.00.

Athira Pharma Stock Performance

Shares of LONA stock opened at $4.76 on Thursday. The firm has a market cap of $18.77 million, a P/E ratio of -0.49 and a beta of 2.72. Athira Pharma has a 1 year low of $2.20 and a 1 year high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.